MiMedx Group (MDXG)

• Market cap: $965M
• 1 day: -1.95%
• 5 days: -6.03%
• 1 month: -17.51%
• 3 months: -28.34%
• 6 months: 14.91%
• Year to date: -29.42%
• 1 year: 2.99%
• 5 years: -9.41%
• 10 years: -36.90%
• Sector: Healthcare
• Industry: Biotechnology

About: MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Employees: 837

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 23

67% more capital invested

Capital invested by funds: $579M [Q3] → $970M (+$391M) [Q4]

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

15% more call options, than puts

Call options by funds: $610K | Put options by funds: $529K

9% more funds holding

Funds holding: 193 [Q3] → 210 (+17) [Q4]

1.85% more ownership

Funds ownership: 66.79% [Q3] → 68.64% (+1.85%) [Q4]

22% less repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 65

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $13 98% upside
• Avg. target: $13 98% upside
• High target: $13 98% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Cantor Fitzgerald Ross Osborn 18% 1-year accuracy 8 / 45 met price target

98% upside $13

Overweight Reiterated

27 Feb 2025